Paperpal Prime Logo

Anti-Cancer Drugs : Impact Factor & More

eISSN: 1473-5741pISSN: 0959-4973

Aims and Scope of Anti-Cancer Drugs

Anti-Cancer Drugs is an international medical journal, which aims to promote and encourage research on anti-cancer agents. It was first published in 1990 and it includes reports on clinical and experimental research results, from conventional cytotoxic chemotherapy to hormonal or biological response modalities. The journal has 10 issues per year and the current editor in chief is Mels Sluyser. According to the 2014 Journal Citation Reports, the journal has an impact factor of 1.784, ranking it 164th out of 211 in the category Oncology and 162nd out of 254 in the category Pharmacology & Pharmacy. Less

Key Metrics

CiteScore
5.2
H-Index
98
Impact Factor
< 5
SJR
Q3Oncology
SNIP
0.52
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Anti-Cancer Drugs

Anti-Cancer Drugs Journal Specifications

Overview
Publisher LIPPINCOTT WILLIAMS & WILKINS
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1990
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Anti-Cancer Drugs ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Anti-Cancer Drugs

Comparative study of the efficacy and safety of PSOX and SOX plus sintilimab regimens as first-line treatments for advanced gastric cancer.
  • 1 Jul 2026
  • Anti-cancer drugs
Fibroblast growth factor receptor 2 mutation-guided targeted therapy with lenvatinib in sebaceous carcinoma of the external auditory canal: a case report and literature review.
  • 1 Jul 2026
  • Anti-cancer drugs
Prolonged multimodal disease control with trifluridine/tipiracil plus bevacizumab in KRAS-mutant metastatic rectal cancer: a case report.
  • 16 Jun 2026
  • Anti-cancer drugs
Growth differentiation factor-11 inhibits the progression of acute myeloid leukemia and increases chemosensitivity by inhibiting cathepsin S.
  • 9 Jun 2026
  • Anti-cancer drugs
Discovery of an orally active and liver-targeted dual prodrug of 5-fluoro-2'-deoxyuridine-5'-monophosphate for the treatment of hepatocellular carcinoma.
  • 3 Jun 2026
  • Anti-cancer drugs
Inavolisib and lenvatinib for PIK3CA-mutated refractory splenic angiosarcoma: a case report.
  • 25 May 2026
  • Anti-cancer drugs
Comparative study of the efficacy and safety of PSOX and SOX plus sintilimab regimens as first-line treatments for advanced gastric cancer.
  • 1 Jul 2026
  • Anti-cancer drugs
Fibroblast growth factor receptor 2 mutation-guided targeted therapy with lenvatinib in sebaceous carcinoma of the external auditory canal: a case report and literature review.
  • 1 Jul 2026
  • Anti-cancer drugs
Prolonged multimodal disease control with trifluridine/tipiracil plus bevacizumab in KRAS-mutant metastatic rectal cancer: a case report.
  • 16 Jun 2026
  • Anti-cancer drugs
Growth differentiation factor-11 inhibits the progression of acute myeloid leukemia and increases chemosensitivity by inhibiting cathepsin S.
  • 9 Jun 2026
  • Anti-cancer drugs
Discovery of an orally active and liver-targeted dual prodrug of 5-fluoro-2'-deoxyuridine-5'-monophosphate for the treatment of hepatocellular carcinoma.
  • 3 Jun 2026
  • Anti-cancer drugs
Inavolisib and lenvatinib for PIK3CA-mutated refractory splenic angiosarcoma: a case report.
  • 25 May 2026
  • Anti-cancer drugs

FAQs on Anti-Cancer Drugs